gantenerumab

Gantenerumab is a fully human IgG1 monoclonal antibody developed for the treatment of Alzheimer's disease. It specifically binds with high affinity to aggregated forms of beta-amyloid (Aβ) peptides, including fibrils and oligomers, by recognizing a conformational epitope that encompasses both N-terminal and central amino acids of Aβ. The drug promotes clearance of amyloid plaques in the brain through Fc gamma receptor-mediated microglial phagocytosis and subsequent lysosomal degradation. Gantenerumab was designed to disassemble and degrade amyloid plaques by recruiting microglia, thereby interrupting aggregation growth and neutralizing oligomer toxicity. Developed by Roche (Hoffmann-La Roche), gantenerumab underwent multiple clinical trials but did not meet primary efficacy endpoints in phase III studies for Alzheimer's disease[1][2][3][4].

Other names

gantenerumab